Nuvation Bio Inc. (NYSE:NUVB) is one of the best high short interest stocks with biggest upside potential. On January 27, Truist raised its price target on Nuvation Bio to $13 from $11 and maintained a Buy rating, citing the Ibtrozi franchise’s robust initial performance as part of a Q4 2025 earnings preview for the biotech sector. Despite seasonal challenges, the firm observed stronger-than-expected market uptake, which positions Ibtrozi as the preferred ROS1 agent over its competitors.
Earlier on January 21, RBC Capital analyst Leonid Timashev raised the price target for Nuvation Bio to $12 from $9 with an Outperform rating. This adjustment followed meetings with management teams, leading the firm to update its financial models for several companies in the biotech sector.
On January 12, H.C. Wainwright lowered its price target for Nuvation Bio Inc. (NYSE:NUVB) to $17 from $18 while maintaining a Buy rating. The firm noted that the company’s preliminary Q4 Ibtrozi net product revenue of ~$15.7 million aligned with its expectations.
Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company that develops therapeutic candidates for oncology.
While we acknowledge the potential of NUVB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
